Please assess the completion status of the following clinical trial:

Trial Title: How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of clinically-definite relapsing-remitting multiple sclerosis~Exclusion Criteria:~* Any Product Information-specified contraindications to interferon-beta therapy, or other medical factors which, in the opinion of the investigator, make the subject unsuitable for interferon-beta therapy~* Use of AVONEX, but not other interferon therapies, in the 3 months prior to randomisation into the study~* A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to randomisation.~* History of seizure in the 3 months prior to randomisation~* History of suicidal ideation or severe depression within the 3 months prior to randomisation.~* Other inclusion and exclusion criteria may apply per study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): titrated dose of Avonex
- 2 (Type: ACTIVE_COMPARATOR): full dose Avonex

Based on this trial design, predict the completion outcome and termination type (if applicable).